thymalfasin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Total Logistic Control is a supply chain company started around 1902 by George K. Taylor. The company began as a regional distributor known as Taylor Cold Storage, which operated frozen warehouse operations for other regional food companies in Great Lakes region. Around 1930, they merged with Wisconsin Cold Storage. In 1958, Taylor became the first public refrigerated warehouse to offer consolidated LTL distribution to its customers. In the 1960s, their total freezer capacity hit 10,000,000 cu ft (280,000 m3). Taylor introduced TINMAN, the Total INformation MANagement system, in 1976, becoming the first firm in the industry to offer online inventory management. In 1982, a flood wiped out the company warehouses, creating the opportunity to refocus the company on third-party logistics as Total Logistic Control. They achieved Foreign Trade Zone status in 1990. Acquired by 'Christiana Companies, Inc' in 1994, the company went into a growth phase. Merging with Wiscold in 1996, starting a Logistics Management Services division in 1999, and then acquiring the ProSource Group in 2000 (offering turnkey facility design). In 2002, they purchased two over-the-road trucking companies of TSI and Birkmire Trucking; taking their fleet total to around 400 tractor-trailers. They were acquired by SuperValu in 2005 and moved their corporate offices to Holland, MI in 2008. Today, TLC is a Source-to-Shelf supply chain company targeting the consumer goods supply chain. 97% of the products they touch end up in retail. Last year that was over 2 billion cases (CEs).
=== Buckman === Wisezah Buckman was the second out of the four to stand trial for the prison attack. Originally, Buckman was slated to be tried in 2020 for the murders, but due to the COVID-19 pandemic in the United States and other reasons, the trial was delayed multiple times until Buckman was finally put on trial in October 2023. On October 19, 2023, Buckman was found guilty of all four counts of first degree murder and ten other felony charges. On November 3, 2023, 35-year-old Wisezah Buckman was sentenced to death, after the jury unanimously recommended three death sentences for three of the murders, while they voted for life without parole for the murder of the fourth victim, Veronica Darden. In 2025, Buckman was transferred from Central Prison to ADX Florence, the same federal prison where Brady is imprisoned.
== Figurative uses == The use of the word "juice" to mean "liquor" (alcohol) dates from 1828. The use of the term "juice" to mean "electricity" dates from 1896. As a verb, the word "juice" was first recorded as meaning "to enliven" in 1964. The adjective "juiced" is recorded as meaning "drunk" in 1946 and "enhanced or as if enhanced by steroids" in 2003. The adjective "juicy" has meant "succulent" since the 15th century (e.g., a juicy roast beef). The figurative meaning "wealthy, full of some desired quality" dates from the 1620s (e.g., a pirate calling a heavily laden ship he aims to plunder a "juicy catch"). The meaning "lively, suggestive, racy, sensational" (e.g., a juicy scandal) is from 1883.
== Music == Half Life (3 album) (2001) Halflife (EP), an EP by Lacuna Coil and the title track Half-Life E.P., an EP by Local H "Half Life", a song by 10 Years from The Autumn Effect "Half Life", a song by Come from Near-Life Experience "Half-Life", a song by Duncan Sheik from Daylight "Half Life", a song by Imogen Heap from her album Ellipse "Half Life", a song by Prototype from the album Trinity "Half Life", a song by Swans from the album Cop "Half Life", a song by Trocadero from the album Roses Are Red, Violets Are Blue "Half-Life", a song by X Ambassadors from the album Townie Halflives, a French-Italian alternative rock band
Laser spectroscopy (or cavity ring-down spectroscopy, CRDS) is able to directly measure 2H/1H, 17O/16O and 18O/16O isotopic composition in water or methane. The use of laser spectroscopy on hydrogen isotopes was first reported by Bergamaschi et al. in 1994. They directly measured 12CH3D/12CH4 in atmospheric methane using a lead salt tunable diode laser spectroscopy. The development of CRDS was first reported by O'Keefe et al. in 1988. In 1999, Kerstel et al. successfully applied this technique to determine HIC in water. The system consists of a laser and a cavity equipped with high finesse reflectivity mirrors. Laser light is injected into the cavity, where the resonance takes place due to the constructive interference. The laser then is turned off. The decay of light intensity is measured. In the presence of a water sample, the photo-absorption by water isotopologues follows the kinetic law. The optical spectrum is obtained by recording ring-down time of the H2O spectral features of interest at certain laser wavelength. The concentration of each isotopologue is proportional to the area under each measured isotopologue spectral feature. Laser spectroscopy is quick, simple, and relatively cheap; and the equipment is portable. So it can be used in the field for measuring water samples. 2H/1H and 18O/16O can be determined simultaneously from a single injection. It requires a small sample size, < 1 μL for water. Typical precision is ~ 1‰. However, this is a compound-specific instrument, i.e. only one specific compound can be measured. And coexisting organic compounds (i.e.
Sources: en.wikipedia.org
Many species have so-called sex chromosomes that determine the sex of each organism. In humans and many other animals, the Y chromosome contains the gene that triggers the development of the specifically male characteristics. In evolution, this chromosome has lost most of its content and also most of its genes, while the X chromosome is similar to the other chromosomes and contains many genes. This being said, Mary Frances Lyon discovered that there is X-chromosome inactivation during reproduction to avoid passing on twice as many genes to the offspring. Lyon's discovery led to the discovery of X-linked diseases.
Gaddafi described his approach to economics as "Islamic socialism". For him, a socialist society could be defined as one in which men controlled their own needs, either through personal ownership or through a collective. Although the early policies pursued by his government were state capitalist in orientation, by 1978 he believed that private ownership of the means of production was exploitative and thus he sought to move Libya away from capitalism and towards socialism. Private enterprise was largely eliminated in favour of a centrally controlled economy. The extent to which Libya became socialist under Gaddafi is disputed. Bearman suggested that while Libya did undergo "a profound social revolution", he did not think that "a socialist society" was established in Libya. Conversely, St. John expressed the view that "if socialism is defined as a redistribution of wealth and resources, a socialist revolution clearly occurred in Libya" under Gaddafi's regime. Gaddafi was staunchly anti-Marxist, and in 1973 declared that "it is the duty of every Muslim to combat" Marxism because it promotes atheism. In his view, ideologies like Marxism and Zionism were alien to the Islamic world and were a threat to the ummah, or global Islamic community. Nevertheless, Blundy and Lycett noted that Gaddafi's socialism had a "curiously Marxist undertone", with political scientist Sami Hajjar arguing that Gaddafi's model of socialism offered a simplification of Karl Marx and Friedrich Engels's theories.
== V == Pablo Valenzuela (b. 1941). Chilean biochemist and biotechnologist at Chiron Corporation (Emeryville, California), known for his genetic studies of hepatitis viruses. Member of the Chilean Academy of Sciences. Ruth van Heyningen (1917–2019). British biochemist at Oxford University, known for her research on the lens and cataracts. Donald Van Slyke (1883–1971). Dutch American biochemist at the Brookhaven National Laboratory noted for the measurement of gas and electrolyte levels in tissues. A unit of measurement for buffering activity, the slyke, is named after him. Member Natl. Acad. Sci. USA. John Craig Venter (1946–2026). American biotechnologist at the J. Craig Venter Institute (Rockville, Maryland), known for human genome sequencing. Member Natl. Acad. Sci. USA. Donald Voet (1938–2023). American biochemist at the University of Pennsylvania known for his textbook Biochemistry. Judith G. Voet (b. 1941). American biochemist at Swarthmore College known for her textbook Biochemistry.
An extensive body of recent experimental research on laboratory animals and documented skeletons has confirmed that habitual muscle recruitment can indeed significantly affect entheseal variation in three-dimensional (3D) morphology - especially when this is quantified based on repeatable and validated morphometric approaches (such as for example V.E.R.A. 1.0 - first introduced in 2016 - and V.E.R.A. 2.0). In contrast, previous research relying on the use of traditional methods (visual scoring systems) has shown that processes associated with aging may have a greater impact than occupational stresses. It has also been shown that geometric changes to bone structure (described above) and scored entheseal changes differ in their underlying cause with the latter little affected by occupation. Joint changes, including osteoarthritis, have been used to infer occupations, but in general these are also manifestations of the aging process. Markers of occupational stress, which include morphological changes to the skeleton and dentition as well as joint changes at specific locations have been widely used to infer specific (rather than general) activities. Such markers are often based on single cases described in late nineteenth century clinical literature. One such marker has been found to be a reliable indicator of lifestyle: the external auditory exostosis also called surfer's ear, which is a small bony protuberance in the ear canal that occurs in those working in proximity to cold water.
Sources: en.wikipedia.org
The Swiss company GlycArt Biotechnology developed a system using CHO cells, where the cells were engineered to overexpress an enzyme called GnTIII. The effect of this overexpression is to block the formation of fucosylated oligosaccharides on the expressed antibodies. This technology was first reported in 1999 and was the basis of GlycArt Biotechnology. Roche acquired GlycArt in 2005 in order to acquire technology to afucosylate antibodies. GlycArt Biotechnology had been founded in 2000 as a spin-out company of the Swiss Federal Institute of Technology in Zurich. The first commercial product from the GlycArt acquisition was obinutuzumab, which as Gazyva gained FDA approval in November 2013 for the treatment of chronic lymphocytic leukemia. Kyowa Hakko Kirin's "Potelligent" platform uses a CHO cell line in which FUT8 has been knocked out, and which produces antibodies with little to no fucose in the Fc region. The company gained marketing approval in Japan in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform. The Company's technology was first reported in 2004.
== History == In 1939, Martin Kamen and Samuel Ruben of the Radiation Laboratory at Berkeley began experiments to determine if any of the elements common in organic matter had isotopes with half-lives long enough to be of value in biomedical research. They synthesized 14C using the laboratory's cyclotron accelerator and soon discovered that the atom's half-life was far longer than had been previously thought. This was followed by a prediction by Serge A. Korff, then employed at the Franklin Institute in Philadelphia, that the interaction of thermal neutrons with 14N in the upper atmosphere would create 14C. It had previously been thought that 14C would be more likely to be created by deuterons interacting with 13C. At some time during World War II, Willard Libby, who was then at Berkeley, learned of Korff's research and conceived the idea that it might be possible to use radiocarbon for dating.
Insulin degludec, marketed as Tresiba and approved in 2015, is an ultra-long-acting insulin with a duration of up to 42 hours. It utilizes multi-hexamer formation and albumin binding to provide a steady insulin release with lower intra-individual variability and greater dosing flexibility. Compared to insulin glargine and detemir, degludec offers a reduced risk of nocturnal hypoglycemia and allows dosing intervals of 8 to 40 hours without compromising glycemic control. These advancements have improved diabetes management by providing more stable blood sugar control, fewer hypoglycemic episodes, and greater convenience for patients. Insulin icodec is, as of 2025, the newest and longest-acting insulin analogue. It has a plasma half-life that is more than eight days, meaning it is a once-weekly insulin. It was approved in 2024 and is marketed as Awiqli by Novo Nordisk. Insulin icodec consists of two peptide chains linked by a disulfide bridge. It contains a C20 fatty diacid-containing side chain, which facilitates strong, reversible binding to albumin. Additionally, three amino acid substitutions are introduced to enhance molecular stability, reduce insulin receptor binding, and slow clearance. These modifications collectively contribute to the prolonged half-life.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.